Progenics Pharmaceuticals Inc

Progenics Pharmaceuticals — Proxy Contest (June 2019)

23 slides from Progenics Pharmaceuticals's proxy contest presentation, Jun 25, 2019

  1. Slide 1: What Really Matters: The Dismal Performance of Progenics Pharmaceuticals

    What Really Matters: The Dismal Performance of Progenics Pharmaceuticals, Inc. Under Peter Crowley and Michael Kishbauch June 25, 2019 Velan Capital, L.P. – ALL RIGHTS RESERVED 1

  2. Slide 2: Disclosure & Disclaimer

    Disclosure & Disclaimer THIS PRESENTATION IS FOR DISCUSSION AND GENERAL INFORMATIONAL PURPOSES ONLY. IT DOES NOT HAVE REGARD TO THE SPECIFIC INVESTMENT OBJECTIVE, FINANCIAL SITUATION, SUITABILITY, OR THE PARTICULAR NEED OF ANY SPECIFIC PERSON WHO MAY RECEIVE THIS PRESENTATION, AND SHOULD NOT BE TAKE

  3. Slide 3: Executive Summary

    Executive Summary  Velan Capital, L.P. (“Velan Capital”), including the other participants in its call for change (“Velan”, “Velan Group”, or “we”), collectively own 9.3% of the outstanding shares of Progenics Pharmaceuticals, Inc. (“PGNX”, “Progenics”, or the “Company”) ― Second-largest stockholde

  4. Slide 4: Hold the PGNX Board Accountable

    Hold the PGNX Board Accountable DISMAL SHARE PRICE PERFORMANCE SPEAKS FOR ITSELF BOARD IS PLAYING A DESPERATE “GAME OF COMPS”, FABRICATING NEW AND INAPPROPRIATE “COMPARABLE” PEER SETS TO SKEW POOR SCORECARD DISINGENUOUS ESG LIP SERVICE, BOARD HAS NOT LOOKED IN THE MIRROR (INSINUATIONS ABOUT INVALIDA

  5. Slide 5: Inconvenient Truths For the Board

    Inconvenient Truths For the Board  Operational Performance ― How AZEDRA went TEN MONTHS before dosing a patient – in our knowledge, the longest period of patient neglect for ANY pharmaceutical product  Why the Board, who deemed AZEDRA “commercialization ready” in 2017 and gave management 133% of i

  6. Slide 6: Inconvenient Truths For the Board (Cont’d)

    Inconvenient Truths For the Board (Cont’d)  Lack of True Alignment with Stockholders ― Together, Messrs. Crowley and Kishbauch actually own ZERO shares of Progenics common stock(1)  In 2018, Messrs. Crowley and Kishbauch earned $452,750 and $237,159, respectively  Meanwhile, PGNX’s stock price de

  7. Slide 7: Board’s Sleight of Hand and Misdirection

    Board’s Sleight of Hand and Misdirection  Stock price performance relative to “peers” ― Progenics cherry-picked its “relevant peers” across various time periods to make its performance look better  Identified EIGHT different peer sets in its June 20th presentation, and ignored the comparable indic

  8. Slide 8: Stock Price Performance

    Stock Price Performance  The following is directly excerpted from the Company’s June 20th presentation (emphasis added):  Note the negative TSR (total stockholder return) across the tenures of Messrs. Baker, Crowley, and Kishbauch  The “Industry Peers” comparison (change) is another form of decep

  9. Slide 9: Stock Price Performance (Cont’d)

    Stock Price Performance (Cont’d)  The following is directly excerpted from the Company’s own 2018 10-K filing (emphasis added): “OLD” PEER GROUP “NEW” PEER GROUP PGNX Source: Company filings. Velan Capital, L.P. – ALL RIGHTS RESERVED 9

  10. Slide 10: “Game of Comps” to Mask the Real Issues

    “Game of Comps” to Mask the Real Issues  In its June 20th presentation, the Company neglects to use the comparable benchmarks from its own 10-K filings for stock price performance. Instead, the Company manufactured EIGHT different and flawed sets of peers to distract from the Board’s DESTRUCTION of

  11. Slide 11: Exposing the Stock Price Gerrymandering

    Exposing the Stock Price Gerrymandering  See below for an analysis of the Company’s chosen 1-year, 3-year and 5-year “peers” ― The minimal overlap between peer sets is troubling ― The Company switches the comparables it uses for its stock price performance charts, which can be misleading  Methodol

  12. Slide 12: Disingenuous “ESG” Lip Service

    Disingenuous “ESG” Lip Service  How can the Board turn a blind eye to Mr. Baker’s seemingly racially-insensitive outburst? ― Mr. Baker upon questioning by Julio Perez (a former Progenics employee who alleged that the Company was making materially misleading claims in a whistleblower lawsuit) during

  13. Slide 13: Velan’s Response to Distorted Allegations

    Velan’s Response to Distorted Allegations  While the focus should be on the Board’s oversight of a persistently underperforming company and NOT on Velan which is not running a competing slate of candidates, we would like to address various false and misleading accusations in order to set the record

  14. Slide 14: Board Holds Itself to a Different Standard

    Board Holds Itself to a Different Standard  The Board has decided to hold Velan to a higher standard than its own directors because, in our view, the Board does not want to be held accountable for its missteps, lack of vision and destruction of stockholder value  Vote the GREEN proxy card to hold

  15. Slide 15: Clarifying Settlement Interactions

    Clarifying Settlement Interactions  The Board notes Velan’s “demands” relative to its “enhanced offers” but: ―The Board does not appear to care about accountability, as none of its counter- proposals contemplated the removal of ANY directors  Velan believes that director accountability is the hall

  16. Slide 16: Vote the GREEN Proxy Card to Fight…

    Vote the GREEN Proxy Card to Fight…  Dismal stock price performance  Entrenchment-minded governance actions designed to disenfranchise stockholders  Unnecessary dilution without stockholder representation  Lack of proper Board oversight, including the appointment and tolerance of an underqualifi

  17. Slide 17: Appendix: What the Board Does Not Want Stockholders to Focus On

    Appendix What the Board Does Not Want Stockholders to Focus On: Key Materials from Velan’s Prior Presentation on Progenics Velan Capital, L.P. – ALL RIGHTS RESERVED 17

  18. Slide 18: Progenics’ Board: An Ugly Report Card

    Progenics’ Board: An Ugly Report Card Peter Crowley Michael Kishbauch (Chairman & (Chair of Nominating & Governance Mark Baker Committee & Member of (CEO & Director) Chair of Compensation Committee) Compensation Committee) Board Tenure 10+ years 5+ years ~10 years Total Stockholder Return (TSR) ~(45

  19. Slide 19: Rewarding Perpetual Underperformance

    Rewarding Perpetual Underperformance Board’s Assessment of Performance Recent Events Performance Goals in Velan’s Commentary Metric 2017 & 2018  AZEDRA is a highly valuable asset with  AZEDRA PDUFA extended and potential to fill an unmet need for cancer subsequently approved in July 2018 patients

  20. Slide 20: Minimal Board Alignment & Ownership

    Minimal Board Alignment & Ownership  Collectively, the non-executive directors own approximately 0.06% of Progenics common stock(1)  Together, Messrs. Crowley and Kishbauch own ZERO shares of Progenics common stock(1) ― In 2018, Messrs. Crowley and Kishbauch earned $452,750 and $237,159, respectiv

  21. Slide 21: AZEDRA: Comparison to Similar Products

    AZEDRA: Comparison to Similar Products  Progenics received approval for AZEDRA in July 2018 and dosed its first patient in June 2019  We could not find ONE other launch that took more than TEN MONTHS to dose a patient  With no Orange Book patents, each day AZEDRA was delayed was a day lost of its

  22. Slide 22: MIP-1095: Blind But Now I See

    MIP-1095: Blind But Now I See  In the six years since acquiring MIP-1095, arguably its most valuable asset, we believe the Board has shown continual neglect and a lack of urgency STANDING STILL AND WATCHING THE COMPETITION PASS BY  It appears to have taken the foresight of Endocyte and its acquisi

  23. Slide 23: Persistent & Unnecessary Dilution

    Persistent & Unnecessary Dilution  Since Chairman Crowley’s reign began in 2009, Progenics has completed equity financings raising more than $200 million, which currently represents over 50% of the Company’s fully-diluted equity value ― In 2018 alone, ~$100 million of dilutive equity was raised  F

Progenics Pharmaceuticals — Proxy Contest (June 2019) on 6ix